What Is PDGFB? Definition and What Research Reports

Definition

PDGFB is the official gene symbol for platelet-derived growth factor subunit B — and, by extension, the name used for the protein chain that gene encodes. The PDGFB polypeptide does not act alone: it folds and then joins a second chain through disulfide bonds to form a dimer, most commonly the homodimer PDGF-BB (or the heterodimer PDGF-AB). That dimer is the biologically active ligand, and it signals principally through the receptor tyrosine kinase PDGFR-β (gene PDGFRB), with weaker activity at PDGFR-α. In the literature, "PDGFB" usually appears in one of three ways: as a gene being mutated, deleted, fused or epigenetically silenced; as a secreted ligand in a signalling pair written "PDGFB/PDGFR-β"; or as the protein PDGF-BB used as a recombinant reagent in cell and animal experiments.

What Class of Molecule Is It?

PDGF-B belongs to the PDGF/VEGF superfamily of secreted growth factors — cysteine-knot proteins built around a conserved eight-cysteine motif. Functionally it is classed as a mitogen and chemoattractant for cells of mesenchymal origin: fibroblasts, smooth muscle cells and, importantly for vascular biology, pericytes.

A point of frequent confusion: PDGFB is a protein (roughly 100+ amino acids per mature chain, glycosylated, disulfide-linked, dimeric), not a short synthetic peptide of the kind that dominates much peptide-research discussion. It sits in the same broad category as VEGF, IGF-1 or FGF-2 — full-length signalling proteins that happen to be studied alongside peptides because they share receptor-ligand logic and are often produced recombinantly for laboratory use.

Where It Comes From

The name reflects its discovery in platelets, which store PDGF in alpha granules and release it on activation. But PDGFB expression is far broader. Endothelial cells are a major source during vessel development, and endothelial-specific manipulation of the gene has been used to probe vascular disease: researchers examining arterio-venous malformation pathogenesis reported that endothelial PDGFB contributes to the disease mechanism in their models (Angiogenesis, 2024). In the central nervous system, microglia have been identified as a PDGFB source: one study reported that microglia-derived PDGFB was required for an intact blood-brain barrier in adult mice (Brain, Behavior, and Immunity, 2024). Macrophages in tumour tissue are another described source, with SPP1-positive macrophages reported to signal to tumour cells through the PDGFB-PDGFRB axis in colorectal cancer liver metastasis (Translational Oncology, 2026).

How the Term Is Used in Peptide and Protein Research

Four usages cover most of the literature:

• As a ligand in a signalling axis. Papers write "PDGFB/PDGFR-β signalling" when describing how a growth factor released by one cell type recruits or stabilises another — classically endothelium recruiting pericytes to a new vessel.
• As a genetic variant. Sequencing studies report PDGFB mutations in inherited conditions; a case report described a novel PDGFB variant in familial brain calcifications with leukoencephalopathy (Neurology: Genetics, 2022).
• As an oncogenic driver. PDGFB is deliberately overexpressed to build tumour models; a longitudinal imaging study profiled RCAS-tva-induced, PDGFB-driven experimental glioma across multiple parameters (Brain Sciences, 2022).
• As a targeting handle. Because PDGFR-β is enriched on some tumour and stromal cells, PDGFB-derived sequences have been attached to nanomaterials for delivery and imaging; one report described a PDGFB-targeting biodegradable FePt alloy assembly used for MRI-guided chemodynamic therapy in cancer models (Journal of Nanobiotechnology, 2022).

What the Published Literature Reports

Vessels and pericytes

The most consistent theme is mural-cell recruitment. In a cerebral ischaemia/reperfusion model, the study reported that edaravone dexborneol limited blood-brain barrier disruption and increased pericyte coverage, with vitronectin-integrin and PDGFB/PDGFR-β signalling implicated as the mechanism (Free Radical Biology & Medicine, 2024). On the developmental side, researchers reported that endothelial PDGFB participates in the pathogenesis of arterio-venous malformations (Angiogenesis, 2024), and a toxicology study reported that prenatal arsenic exposure disrupted placental angiogenesis by altering epigenetic modification of the Pdgfb promoter (Journal of Hazardous Materials, 2025).

Brain barrier and neural signalling

Two microglia-focused papers extended PDGFB beyond classical vascular biology. One reported that an integral blood-brain barrier in adulthood relied on microglia-derived PDGFB (Brain, Behavior, and Immunity, 2024). The other reported that microglia-derived PDGFB promoted neuronal potassium currents, which suppressed basal sympathetic tonicity and limited hypertension in the models studied (Immunity, 2022) — a neuro-immune role distinct from vessel stabilisation.

Tumour biology

PDGFB appears both as a driver and as a regulated transcript. A clinicopathological analysis described the COL1A1-PDGFB gene fusion as a useful diagnostic tool in dermatofibrosarcoma protuberans (International Journal of Clinical and Experimental Pathology, 2018). In glioma, researchers reported that RBFOX2 suppressed NETosis and tumour growth through 5hmC-dependent decay of PDGFB transcripts (Cell Reports, 2026), while the PDGFB-driven RCAS-tva glioma model was characterised longitudinally for imaging and biological parameters (Brain Sciences, 2022).

Summary table

Disease Associations: What Studies Report

PDGFB is not a compound administered to people in the literature listed here, so there is no human adverse-event profile to summarise. What the published record does describe is pathology associated with dysregulation of the gene or its signalling. Gain-of-function rearrangement was reported in the form of the COL1A1-PDGFB fusion in dermatofibrosarcoma protuberans (International Journal of Clinical and Experimental Pathology, 2018); sustained PDGFB expression was used to generate gliomas in an experimental model (Brain Sciences, 2022); and loss-of-function variants were reported in familial brain calcifications with leukoencephalopathy (Neurology: Genetics, 2022). In other words, the literature describes consequences in both directions — too much signalling in tumour contexts, too little in vascular and calcification phenotypes. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or condition.

Terms Often Confused With PDGFB

• PDGFB vs PDGF-BB. PDGFB is the gene/single chain; PDGF-BB is the active homodimer of two B chains.
• PDGFB vs PDGFRB. The first is the ligand, the second the receptor it binds. Papers often study them as a pair, as in the reported PDGFB-PDGFRB crosstalk in metastasis (Translational Oncology, 2026).
• PDGFB vs PDGFA/C/D. Four separate genes encode four PDGF chains with different receptor preferences; findings for one do not transfer to the others.
• Italics matter. PDGFB (human gene) and Pdgfb (rodent gene) are written in italics; PDGF-B, the protein, is not.

Limitations of the Current Record

Most of the work cited here is preclinical — mouse models, tumour models, cell systems and single-family genetic reports — and none of it establishes that manipulating PDGFB is safe or useful as a therapy in people. Effects reported in one tissue, such as barrier maintenance in the adult brain (Brain, Behavior, and Immunity, 2024), cannot be assumed to hold in another, given that the same axis was reported to support tumour-promoting crosstalk elsewhere (Translational Oncology, 2026). Recombinant PDGF-BB and PDGFB-targeting constructs described in these papers are laboratory reagents used in research settings.

References

• Role of endothelial PDGFB in arterio-venous malformations pathogenesis (Angiogenesis, 2024)
• Familial Brain Calcifications With Leukoencephalopathy: A Novel PDGFB Variant (Neurology: Genetics, 2022)
• Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension (Immunity, 2022)
• Multiparametric Longitudinal Profiling of RCAS-tva-Induced PDGFB-Driven Experimental Glioma (Brain Sciences, 2022)
• Edaravone Dexborneol protects against blood-brain barrier disruption following cerebral ischemia/reperfusion by upregulating pericyte coverage via vitronectin-integrin and PDGFB/PDGFR-β signaling (Free Radical Biology & Medicine, 2024)
• Prenatal arsenic exposure disrupts placental angiogenesis by altering Pdgfb promoter epigenetic modification (Journal of Hazardous Materials, 2025)
• SPP1⁺ macrophage-FADS1⁺ tumor cell crosstalk via the PDGFB-PDGFRB axis drives liver metastasis in colorectal cancer (Translational Oncology, 2026)
• COL1A1-PDGFB gene fusion in dermatofibrosarcoma protuberans: a useful diagnostic tool and clinicopathological analysis (International Journal of Clinical and Experimental Pathology, 2018)
• RBFOX2 suppresses NETosis and glioma growth via 5hmC-dependent PDGFB decay (Cell Reports, 2026)
• An integral blood-brain barrier in adulthood relies on microglia-derived PDGFB (Brain, Behavior, and Immunity, 2024)
• PDGFB targeting biodegradable FePt alloy assembly for MRI guided starvation-enhancing chemodynamic therapy of cancer (Journal of Nanobiotechnology, 2022)